{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:19:04Z","timestamp":1792624744459,"version":"4.5.0"},"reference-count":54,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The effect of direct\u2010acting anti\u2010virals (DAAs) in children and adolescents with chronic hepatitis C virus (HCV) infection is difficult to determine, since few, aged between 3 and 18\u00a0years, have been enrolled in clinical trials, and some data come from observational studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To summarise the evidence on efficacy and safety of DAAs in children and adolescents with chronic HCV infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a systematic review and meta\u2010analysis of prospective studies on the efficacy and safety of DAAs in subjects &lt;18\u00a0years of age. We considered the sustained virological response at post\u2010treatment week 12 as efficacy outcome and adverse events as safety outcome. We considered intervention effect for each study arm by calculating the proportion of sustained virologic response at post\u2010treatment week 12 in subjects receiving all doses of treatment and proportion of adverse events in subjects receiving at least one dose of treatment. Pooled proportions were calculated using the Freeman\u2010Tukey double arcsine transformation. Random effects model was used for all analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 39 included studies (1796 subjects), the pooled proportion among those receiving all doses of treatment and reaching sustained virologic response at post\u2010treatment week 12 was 100% (95% confidence interval: 100\u2010100). Considering subjects receiving at least one dose of treatment, lowest estimates were reported among children  with cirrhosis (83%). Headache and fatigue were the most common adverse events. Serious adverse events were uncommon.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Children and adolescents with chronic HCV infection can be safely treated with DAAs with similar efficacy as reported in adults.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.16037","type":"journal-article","created":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T07:46:57Z","timestamp":1607068017000},"page":"1125-1133","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Systematic review with meta\u2010analysis: the efficacy and safety of direct\u2010acting antivirals in children and adolescents with chronic hepatitis C virus infection"],"prefix":"10.1111","volume":"52","author":[{"given":"Giuseppe","family":"Indolfi","sequence":"first","affiliation":[{"name":"Paediatric and Liver Unit Meyer Children's University Hospital of Florence Firenze Italy"},{"name":"Department NEUROFARBA University of Florence Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Giometto","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine University of Pisa Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Serranti","sequence":"additional","affiliation":[{"name":"Paediatric and Liver Unit Meyer Children's University Hospital of Florence Firenze Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bettiol","sequence":"additional","affiliation":[{"name":"Department NEUROFARBA University of Florence Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bigagli","sequence":"additional","affiliation":[{"name":"Department NEUROFARBA University of Florence Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"De Masi","sequence":"additional","affiliation":[{"name":"Clinical Trial Office Meyer's Children University Hospital of Florence Firenze Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5608-5902","authenticated-orcid":false,"given":"Ersilia","family":"Lucenteforte","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine University of Pisa Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30385-1"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30046-9"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30123"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28995"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29278"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30821"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30830"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30840"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14502"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001360"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001838"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14677"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v7.i16.2247"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002189"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piz041"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13032"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1250"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2017.06.002"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-018-2752-7"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001217"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002449"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001968"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.346.15722"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2019.12.034"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14308"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piaa006"},{"key":"e_1_2_7_30_1","first-page":"423","article-title":"Effectiveness and safety of sofosbuvir in treatment\u2010n\u00e4ivechildren with hepatitis C infection","volume":"27","author":"Hashmi MA","year":"2017","journal-title":"J Coll Physicians Surg Pak"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002139"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-019-09985-w"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002101"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30388-3"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30642-6"},{"key":"e_1_2_7_36_1","first-page":"LVH\u201007","article-title":"Safety and efficacy of sofosbuvir (SOF), ledipasvir (LDV) and daclatasvir (DCT) in thalassemic patients with chronic hepatitis C: a single center experience","volume":"35","author":"Patel R","year":"2016","journal-title":"Indian J Gastroenterol"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)31278-9"},{"key":"e_1_2_7_38_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0618-8278(19)30411-6","article-title":"THU\u2010136\u2010Ledipasvir\/sofosbuvir for 8 weeks cures genotype 4 chronic hepatitis C in non\u2010cirrhotic children and adolescents","volume":"70","author":"El\u2010Sayed MH","year":"2019","journal-title":"J Hepatol"},{"key":"e_1_2_7_39_1","first-page":"LP10","article-title":"Development of a novel model to support elbasvir\/grazoprevir use in children with chronic hepatitis C virus genotypes 1 or 4 infection","volume":"70","author":"Gonzalez\u2010Peralta RP","year":"2019","journal-title":"Hepatology"},{"key":"e_1_2_7_40_1","first-page":"465A","article-title":"Safety and Efficacy of Sofosbuvir\/Velpatasvir in Pediatric Patients 6 to <18 Years Old with Chronic Hepatitis C Infection","volume":"70","author":"Jonas MM","year":"2019","journal-title":"Hepatology"},{"key":"e_1_2_7_41_1","first-page":"890","article-title":"Sofosbuvir\/Ledipasvir in adolescents 12\u201317 years old with hepatitis C virus genotype 1, 3 or 4 infection: a real\u2010world experience","volume":"68","author":"Serranti D","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)30748-7"},{"issue":"2","key":"e_1_2_7_43_1","first-page":"S515","article-title":"Outcomes of sofosbuvir and ribavirin treatment combination in HEP C G3 pediatric patients","volume":"12","author":"Gill ML","year":"2018","journal-title":"Hepatol Int"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000593680.36839.bf"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy585"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001589"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001872"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13111"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001754"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12830"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.082"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2015.1070668"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07293.x"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e318229d96f"},{"key":"e_1_2_7_55_1","unstructured":"World Health Organization. Progress report on access to hepatitis C treatment: focus on overcoming barriers in low\u2010 and middle\u2010income countries 2018;https:\/\/apps.who.int\/iris\/handle\/10665\/260445. License: CC BY\u2010NC\u2010SA 3.0 IGO"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.16037","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.16037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T17:33:34Z","timestamp":1729618414000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.16037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,18]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1111\/apt.16037"],"URL":"https:\/\/doi.org\/10.1111\/apt.16037","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,18]]},"assertion":[{"value":"2020-04-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}